1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Crohn's Disease - Pipeline Review, H2 2014

Crohn's Disease - Pipeline Review, H2 2014

  • October 2014
  • -
  • Global Markets Direct
  • -
  • 390 pages

Crohn's Disease - Pipeline Review, H2 2014

Summary

Global Markets Direct’s, ‘Crohn's Disease - Pipeline Review, H2 2014’, provides an overview of the Crohn's Disease’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Crohn's Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Crohn's Disease and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Crohn's Disease
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Crohn's Disease and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Crohn's Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Crohn's Disease pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Crohn's Disease
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Crohn's Disease pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Crohn's Disease - Pipeline Review, H2 2014
Table of Contents
Table of Contents 2
List of Tables 8
List of Figures 11
Introduction 12
Global Markets Direct Report Coverage 12
Crohn's Disease Overview 13
Therapeutics Development 14
Pipeline Products for Crohn's Disease - Overview 14
Pipeline Products for Crohn's Disease - Comparative Analysis 15
Crohn's Disease - Therapeutics under Development by Companies 16
Crohn's Disease - Therapeutics under Investigation by Universities/Institutes 24
Crohn's Disease - Pipeline Products Glance 25
Late Stage Products 25
Clinical Stage Products 26
Early Stage Products 27
Unknown Stage Products 28
Crohn's Disease - Products under Development by Companies 29
Crohn's Disease - Products under Investigation by Universities/Institutes 37
Crohn's Disease - Companies Involved in Therapeutics Development 38
4SC AG 38
AB Science 39
AbbVie Inc. 40
Alba Therapeutics Corporation 41
Alfa Wassermann S.p.A 42
Allozyne, Inc. 43
AlphaMab Co., Ltd 44
Amgen Inc. 46
Ampio Pharmaceuticals, Inc. 47
Amunix, Inc. 48
AstraZeneca PLC 49
Biocon Limited 50
BioLineRx, Ltd. 51
Boehringer Ingelheim GmbH 52
Bristol-Myers Squibb Company 53
Calypso Biotech SA 54
Celgene Corporation 55
Celltrion, Inc. 56
ChemoCentryx, Inc. 57
ChironWells GmbH 58
CIMAB S.A. 59
CLL Pharma 60
Daiichi Sankyo Company, Limited 61
DBV Technologies SA 62
Delenex Therapeutics AG 63
Effimune SAS 64
Eisai Co., Ltd. 65
Eli Lilly and Company 66
Emergent BioSolutions Inc. 67
Enlivex Therapeutics Ltd 68
Enzo Biochem, Inc. 69
Epirus Biopharmaceuticals, Inc. 70
Farmacija d.o.o. Tuzla 71
Ferring International Center S.A. 72
Galapagos NV 73
Genfit SA 74
Genor BioPharma Co., Ltd. 75
Gilead Sciences, Inc. 76
GT Biologics Limited 77
iCo Therapeutics Inc. 78
Immune Response BioPharma, Inc. 79
Immunotherapix SAS 80
Inbiopro Solutions Pvt. Ltd. 81
InflammatoRx inc. 82
Innovent Biologics, Inc. 83
Innovimmune Biotherapeutics, Inc. 84
Inovio Pharmaceuticals, Inc. 85
Johnson and Johnson 86
Kangstem Holdings Co., Ltd. 87
Kyorin Pharmaceutical Co., Ltd. 88
Medestea Research and Production S.p.A. 89
Mesoblast Limited 90
Mitsubishi Tanabe Pharma Corporation 91
Neovacs SA 92
Novo Nordisk A/S 93
Oncobiologics, Inc. 94
Oncodesign SA 95
Pfizer Inc. 96
Pieris AG 97
Pluristem Therapeutics Inc. 98
Protalix BioTherapeutics, Inc. 99
Qu Biologics Inc. 100
RedHill Biopharma Ltd. 101
S.L.A. Pharma AG 102
Sandoz Inc. 103
Sanofi 104
Selexys Pharmaceuticals Corporation 105
Sigmoid Pharma Limited 106
Soligenix, Inc. 107
Stelic Institute and Co. 108
Sylentis S.A. 109
Takeda Pharmaceutical Company Limited 110
Teva Pharmaceutical Industries Limited 111
Tillotts Pharma AG 112
Toray Industries, Inc. 113
Trino Therapeutics Ltd 114
TxCell SA 115
Virobay Inc. 116
Winston Pharmaceuticals, Inc. 117
Crohn's Disease - Therapeutics Assessment 118
Assessment by Monotherapy Products 118
Assessment by Combination Products 119
Assessment by Target 120
Assessment by Mechanism of Action 124
Assessment by Route of Administration 128
Assessment by Molecule Type 130
Drug Profiles 132
(mesalamine + N-acetylcysteine) - Drug Profile 132
(metenkefalin + tridecactide) - Drug Profile 134
(rifabutin + clarithromycin + clofazimine) - Drug Profile 135
AB-0045 - Drug Profile 137
abrilumab - Drug Profile 138
ABS-11 - Drug Profile 140
adalimumab - Drug Profile 141
adalimumab biosimilar - Drug Profile 143
adalimumab biosimilar - Drug Profile 144
adalimumab biosimilar - Drug Profile 146
adalimumab biosimilar - Drug Profile 147
adalimumab biosimilar - Drug Profile 148
adalimumab biosimilar - Drug Profile 149
adalimumab biosimilar - Drug Profile 150
adalimumab biosimilar - Drug Profile 151
adalimumab biosimilar - Drug Profile 152
adalimumab biosimilar - Drug Profile 153
Alequel - Drug Profile 154
AMG-139 - Drug Profile 155
Ampion - Drug Profile 156
AMX-256 - Drug Profile 158
Anti-S100A9 Monoclonal Antibody - Drug Profile 159
Antibodies to Inhibit MMP-2 and MMP-9 for Immunology and Gastrointestinal Disorders - Drug Profile 160
Antibodies to Target Metallothioneins for Ulcerative Colitis and Crohns Disease - Drug Profile 161
ApoCell - Drug Profile 162
apremilast - Drug Profile 163
Atrosab - Drug Profile 165
AZ-17 - Drug Profile 166
bertilimumab - Drug Profile 167
BI-655066 - Drug Profile 169
Biologic for Crohn's Disease - Drug Profile 170
BL-5040 - Drug Profile 171
budesonide ER - Drug Profile 172
CALY-001 - Drug Profile 174
cenplacel-L - Drug Profile 175
cyclosporine - Drug Profile 177
Dendritic Cell Therapy for Crohn's Disease - Drug Profile 178
DLX-105 - Drug Profile 179
Drug for Crohn's Disease - Drug Profile 181
Drugs to Inhibit TNFR25 for Gastrointestinal Disorders - Drug Profile 182
E-6011 - Drug Profile 183
eldelumab - Drug Profile 184
ES-210 - Drug Profile 186
etanercept biosimilar - Drug Profile 187
ETX-201 - Drug Profile 188
FE-999301 - Drug Profile 189
FFP-102 - Drug Profile 190
filgotinib - Drug Profile 191
Furestem-CD - Drug Profile 193
GED-0301 - Drug Profile 194
GFT-505 - Drug Profile 195
IAC VITA - Drug Profile 198
IBI-303 - Drug Profile 200
IBPM-004AM - Drug Profile 201
IBPM-005IX - Drug Profile 202
infliximab - Drug Profile 203
infliximab biosimilar - Drug Profile 205
infliximab biosimilar - Drug Profile 207
infliximab biosimilar - Drug Profile 208
INV-88 - Drug Profile 209
IR-777 - Drug Profile 210
ITP-01 - Drug Profile 211
JKB-122 - Drug Profile 212
JNJ-40346527 - Drug Profile 214
KRP-203 - Drug Profile 216
larazotide acetate - Drug Profile 218
LBP-001 - Drug Profile 220
Leukothera - Drug Profile 221
masitinib - Drug Profile 222
mercaptopurine DR - Drug Profile 225
mesalamine CR - Drug Profile 226
metronidazole - Drug Profile 227
MLN-3126 - Drug Profile 229
Monoclonal Antibody to Inhibit TNF Alpha for Crohns Disease and Rheumatoid Arthritis - Drug Profile 230
MP-196 - Drug Profile 231
MT-1303 - Drug Profile 232
naltrexone - Drug Profile 233
naltrexone - Drug Profile 234
NAT-100 - Drug Profile 235
NN-8555 - Drug Profile 236
NN-8828 - Drug Profile 237
ONS-3015 - Drug Profile 239
Ova-Treg - Drug Profile 240
Peptides to Inhibit IL-1 Beta for Ulcerative Colitis and Crohn's Disease - Drug Profile 242
PF-00547659 - Drug Profile 243
PF-04236921 - Drug Profile 245
PF-06480605 - Drug Profile 246
PH-44 - Drug Profile 247
PH-46A - Drug Profile 248
PH-5 - Drug Profile 249
PRS-190 - Drug Profile 250
QBECO - Drug Profile 251
remestemcel-L - Drug Profile 253
rifaximin - Drug Profile 255
rifaximin DR - Drug Profile 257
RNAi Oligonucleotide for Arthritis and Gastrointestinal Disorders - Drug Profile 258
SAR-252067 - Drug Profile 259
SelK-2 - Drug Profile 260
SGX-203 - Drug Profile 261
Small Molecule to Agonize OP3 Receptor for Inflammatory Bowel Diseases - Drug Profile 262
Small Molecules for Gastrointestinal Disorders - Drug Profile 263
Small Molecules to Inhibit RIP2 for Crohn's Disease and Polyarthritis - Drug Profile 264
SQ-641 - Drug Profile 265
Stem Cell Therapy for Crohn's Disease - Drug Profile 266
Stem Cell Therapy for Inflammatory Bowel Disease - Drug Profile 267
STNM-01 - Drug Profile 268
SYN-1002 - Drug Profile 269
TNF-Kinoid - Drug Profile 270
tofacitinib - Drug Profile 272
TRK-170 - Drug Profile 276
ustekinumab - Drug Profile 277
VBY-036 - Drug Profile 280
vedolizumab - Drug Profile 281
vercirnon sodium - Drug Profile 283
VGX-1027 - Drug Profile 285
vidofludimus - Drug Profile 286
zucapsaicin - Drug Profile 290
Crohn's Disease - Recent Pipeline Updates 292
Crohn's Disease - Dormant Projects 367
Crohn's Disease - Discontinued Products 371
Crohn's Disease - Product Development Milestones 372
Featured News and Press Releases 372
Appendix 381
Methodology 381
Coverage 381
Secondary Research 381
Primary Research 381
Expert Panel Validation 381
Contact Us 382
Disclaimer 382

List of Tables

Number of Products under Development for Crohn's Disease, H2 2014 22
Number of Products under Development for Crohn's Disease - Comparative Analysis, H2 2014 23
Number of Products under Development by Companies, H2 2014 25
Number of Products under Development by Companies, H2 2014 (Contd..1) 26
Number of Products under Development by Companies, H2 2014 (Contd..2) 27
Number of Products under Development by Companies, H2 2014 (Contd..3) 28
Number of Products under Development by Companies, H2 2014 (Contd..4) 29
Number of Products under Development by Companies, H2 2014 (Contd..5) 30
Number of Products under Development by Companies, H2 2014 (Contd..6) 31
Number of Products under Investigation by Universities/Institutes, H2 2014 32
Comparative Analysis by Late Stage Development, H2 2014 33
Comparative Analysis by Clinical Stage Development, H2 2014 34
Comparative Analysis by Early Stage Development, H2 2014 35
Comparative Analysis by Unknown Stage Development, H2 2014 36
Products under Development by Companies, H2 2014 37
Products under Development by Companies, H2 2014 (Contd..1) 38
Products under Development by Companies, H2 2014 (Contd..2) 39
Products under Development by Companies, H2 2014 (Contd..3) 40
Products under Development by Companies, H2 2014 (Contd..4) 41
Products under Development by Companies, H2 2014 (Contd..5) 42
Products under Development by Companies, H2 2014 (Contd..6) 43
Products under Development by Companies, H2 2014 (Contd..7) 44
Products under Investigation by Universities/Institutes, H2 2014 45
Crohn's Disease - Pipeline by 4SC AG, H2 2014 46
Crohn's Disease - Pipeline by AB Science, H2 2014 47
Crohn's Disease - Pipeline by AbbVie Inc., H2 2014 48
Crohn's Disease - Pipeline by Alba Therapeutics Corporation, H2 2014 49
Crohn's Disease - Pipeline by Alfa Wassermann S.p.A, H2 2014 50
Crohn's Disease - Pipeline by Allozyne, Inc., H2 2014 51
Crohn's Disease - Pipeline by AlphaMab Co., Ltd, H2 2014 52
Crohn's Disease - Pipeline by Altheus Therapeutics, Inc., H2 2014 53
Crohn's Disease - Pipeline by Amgen Inc., H2 2014 54
Crohn's Disease - Pipeline by Ampio Pharmaceuticals, Inc., H2 2014 55
Crohn's Disease - Pipeline by Amunix, Inc., H2 2014 56
Crohn's Disease - Pipeline by AstraZeneca PLC, H2 2014 57
Crohn's Disease - Pipeline by Biocon Limited, H2 2014 58
Crohn's Disease - Pipeline by BioLineRx, Ltd., H2 2014 59
Crohn's Disease - Pipeline by Boehringer Ingelheim GmbH, H2 2014 60
Crohn's Disease - Pipeline by Bristol-Myers Squibb Company, H2 2014 61
Crohn's Disease - Pipeline by Calypso Biotech SA, H2 2014 62
Crohn's Disease - Pipeline by Celgene Corporation, H2 2014 63
Crohn's Disease - Pipeline by Celltrion, Inc., H2 2014 64
Crohn's Disease - Pipeline by ChemoCentryx, Inc., H2 2014 65
Crohn's Disease - Pipeline by ChironWells GmbH, H2 2014 66
Crohn's Disease - Pipeline by CIMAB S.A., H2 2014 67
Crohn's Disease - Pipeline by CLL Pharma, H2 2014 68
Crohn's Disease - Pipeline by Daiichi Sankyo Company, Limited, H2 2014 69
Crohn's Disease - Pipeline by DBV Technologies SA, H2 2014 70
Crohn's Disease - Pipeline by Delenex Therapeutics AG, H2 2014 71
Crohn's Disease - Pipeline by Effimune SAS, H2 2014 72
Crohn's Disease - Pipeline by Eisai Co., Ltd., H2 2014 73
Crohn's Disease - Pipeline by Eli Lilly and Company, H2 2014 74
Crohn's Disease - Pipeline by Emergent BioSolutions Inc., H2 2014 75
Crohn's Disease - Pipeline by Enlivex Therapeutics Ltd, H2 2014 76
Crohn's Disease - Pipeline by Enzo Biochem, Inc., H2 2014 77
Crohn's Disease - Pipeline by Epirus Biopharmaceuticals, Inc., H2 2014 78
Crohn's Disease - Pipeline by Farmacija d.o.o. Tuzla, H2 2014 79
Crohn's Disease - Pipeline by Ferring International Center S.A., H2 2014 80
Crohn's Disease - Pipeline by Galapagos NV, H2 2014 81
Crohn's Disease - Pipeline by Genfit SA, H2 2014 82
Crohn's Disease - Pipeline by Genor BioPharma Co., Ltd., H2 2014 83
Crohn's Disease - Pipeline by Gilead Sciences, Inc., H2 2014 84
Crohn's Disease - Pipeline by GT Biologics Limited, H2 2014 85
Crohn's Disease - Pipeline by iCo Therapeutics Inc., H2 2014 86
Crohn's Disease - Pipeline by Immune Response BioPharma, Inc., H2 2014 87
Crohn's Disease - Pipeline by Immunotherapix SAS, H2 2014 88
Crohn's Disease - Pipeline by Inbiopro Solutions Pvt. Ltd., H2 2014 89
Crohn's Disease - Pipeline by InflammatoRx inc., H2 2014 90
Crohn's Disease - Pipeline by Innovent Biologics, Inc., H2 2014 91
Crohn's Disease - Pipeline by Innovimmune Biotherapeutics, Inc., H2 2014 92
Crohn's Disease - Pipeline by Inovio Pharmaceuticals, Inc., H2 2014 93
Crohn's Disease - Pipeline by Johnson and Johnson, H2 2014 94
Crohn's Disease - Pipeline by Kangstem Holdings Co., Ltd., H2 2014 95
Crohn's Disease - Pipeline by Kyorin Pharmaceutical Co., Ltd., H2 2014 96
Crohn's Disease - Pipeline by Medestea Research and Production S.p.A., H2 2014 97
Crohn's Disease - Pipeline by Mesoblast Limited, H2 2014 98
Crohn's Disease - Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2014 99
Crohn's Disease - Pipeline by Neovacs SA, H2 2014 100
Crohn's Disease - Pipeline by Novo Nordisk A/S, H2 2014 101
Crohn's Disease - Pipeline by Oncobiologics, Inc., H2 2014 102
Crohn's Disease - Pipeline by Oncodesign SA, H2 2014 103
Crohn's Disease - Pipeline by Pfizer Inc., H2 2014 104
Crohn's Disease - Pipeline by Pieris AG, H2 2014 105
Crohn's Disease - Pipeline by Pluristem Therapeutics Inc., H2 2014 106
Crohn's Disease - Pipeline by Protalix BioTherapeutics, Inc., H2 2014 107
Crohn's Disease - Pipeline by Qu Biologics Inc., H2 2014 108
Crohn's Disease - Pipeline by RedHill Biopharma Ltd., H2 2014 109
Crohn's Disease - Pipeline by S.L.A. Pharma AG, H2 2014 110
Crohn's Disease - Pipeline by Sandoz Inc., H2 2014 111
Crohn's Disease - Pipeline by Sanofi, H2 2014 112
Crohn's Disease - Pipeline by Selexys Pharmaceuticals Corporation, H2 2014 113
Crohn's Disease - Pipeline by Sigmoid Pharma Limited, H2 2014 114
Crohn's Disease - Pipeline by Soligenix, Inc., H2 2014 115
Crohn's Disease - Pipeline by Stelic Institute and Co., H2 2014 116
Crohn's Disease - Pipeline by Sylentis S.A., H2 2014 117
Crohn's Disease - Pipeline by Takeda Pharmaceutical Company Limited, H2 2014 118
Crohn's Disease - Pipeline by Teva Pharmaceutical Industries Limited, H2 2014 119
Crohn's Disease - Pipeline by Tillotts Pharma AG, H2 2014 120
Crohn's Disease - Pipeline by Toray Industries, Inc., H2 2014 121
Crohn's Disease - Pipeline by Trino Therapeutics Ltd, H2 2014 122
Crohn's Disease - Pipeline by TxCell SA, H2 2014 123
Crohn's Disease - Pipeline by Virobay Inc., H2 2014 124
Crohn's Disease - Pipeline by Winston Pharmaceuticals, Inc., H2 2014 125
Assessment by Monotherapy Products, H2 2014 126
Assessment by Combination Products, H2 2014 127
Number of Products by Stage and Target, H2 2014 129
Number of Products by Stage and Mechanism of Action, H2 2014 133
Number of Products by Stage and Route of Administration, H2 2014 137
Number of Products by Stage and Molecule Type, H2 2014 139
Crohn's Disease Therapeutics - Recent Pipeline Updates, H2 2014 300
Crohn's Disease - Dormant Projects, H2 2014 375
Crohn's Disease - Discontinued Products, H2 2014 379

List of Figures
Number of Products under Development for Crohn's Disease, H2 2014 22
Number of Products under Development for Crohn's Disease - Comparative Analysis, H2 2014 23
Number of Products under Development by Companies, H2 2014 24
Number of Products under Investigation by Universities/Institutes, H2 2014 32
Comparative Analysis by Late Stage Development, H2 2014 33
Comparative Analysis by Clinical Stage Development, H2 2014 34
Comparative Analysis by Early Stage Products, H2 2014 35
Assessment by Monotherapy Products, H2 2014 126
Assessment by Combination Products, H2 2014 127
Number of Products by Top 10 Targets, H2 2014 128
Number of Products by Stage and Top 10 Targets, H2 2014 128
Number of Products by Top 10 Mechanism of Actions, H2 2014 132
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014 132
Number of Products by Top 10 Routes of Administration, H2 2014 136
Number of Products by Stage and Top 10 Routes of Administration, H2 2014 136
Number of Products by Top 10 Molecule Types, H2 2014 138
Number of Products by Stage and Top 10 Molecule Types, H2 2014 138

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Liver Cirrhosis- Market Insights, Epidemiology and Market Forecast-2023

Liver Cirrhosis- Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Liver Cirrhosis - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global ...

Peptic Ulcer  - Market Insights, Epidemiology and Market Forecast-2023

Peptic Ulcer  - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Peptic Ulcer - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global ...

Crohn’s disease (CD)- Market Insights, Epidemiology and Market Forecast-2023

Crohn’s disease (CD)- Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Crohn’s disease (CD) - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.